Among the targeted agents, the monoclonal antibody trastuzumab (Herceptin), which is used in women with both metastatic and early-stage breast cancer, has probably received the most attention for its cardiotoxicit

This entry was posted on Tuesday, March 9th, 2010 at 9:06 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.